Role of 18F-Fluorodeoxyglucose Positron-Emission Tomography (FDG-PET) in the Management of Pancreatic Cancer

2019 ◽  
pp. 175-185
Author(s):  
Chad A. Barnes ◽  
Michael Holt ◽  
Susan Tsai
Keyword(s):  
Pancreatic Cancer ◽  
Positron Emission Tomography ◽  
Fdg Pet ◽  
Emission Tomography ◽  
Fluorodeoxyglucose Positron Emission Tomography ◽  
18F Fluorodeoxyglucose ◽  
Positron Emission ◽  
Fluorodeoxyglucose Positron Emission

scholarly journals The emerging role of whole-body 18F-fluorodeoxyglucose positron emission tomography in patients with sarcoidosis

2012 ◽  
pp. 21-26 ◽  
Author(s):  
Silvia Taralli ◽  
Giorgio Treglia ◽  
Alessandro Giordano
Keyword(s):  
Positron Emission Tomography ◽  
Fdg Pet ◽  
Emission Tomography ◽  
Whole Body ◽  
Imaging Method ◽  
Fluorodeoxyglucose Positron Emission Tomography ◽  
18F Fluorodeoxyglucose ◽  
Positron Emission ◽  
Fluorodeoxyglucose Positron Emission

IntroductionThe purpose of this article is to examine the emerging role of whole-body positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG) in patients with sarcoidosis.Materials and methodsWe reviewed the literature on the use of FDG-PET in patients with sarcoidosis to identify how this technique is being applied in clinical practice.Results and discussionOur review shows that: 1) sarcoidosis is commonly associated with increased FDG uptake. Therefore, positive findings should be interpreted with caution when FDG-PET is being used to distinguish benign from malignant abnormalities; 2) FDG-PET seems to be a very useful molecular imaging method for staging sarcoidosis, identification of occult sites of involvement, guiding biopsy procedures, and monitoring patients’ responses to treatment; and 3) in patients with sarcoidosis, the diagnostic accuracy of FDG-PET is superior to that of 67Ga scintigraphy.

scholarly journals The Role of 18F-Fluorodeoxyglucose Positron Emission Tomography in the Prognostication, Diagnosis, and Management of Thyroid Carcinoma

2012 ◽  
Vol 2012 ◽  
pp. 1-8 ◽  
Author(s):  
Brian Hung-Hin Lang
Keyword(s):  
Positron Emission Tomography ◽  
Thyroid Carcinoma ◽  
Fdg Pet ◽  
Emission Tomography ◽  
Fluorodeoxyglucose Positron Emission Tomography ◽  
Diagnosis And Management ◽  
18F Fluorodeoxyglucose ◽  
Radioiodine Ablation ◽  
Positron Emission ◽  
Fluorodeoxyglucose Positron Emission

18F-fluorodeoxyglucose positron emission tomography (FDG-PET) plays an increasingly important role in the prognostication, diagnosis, and management of thyroid carcinoma. For patients diagnosed with primary or persistent/recurrent thyroid carcinoma, a finding of FDG-PET positivity implies a more aggressive tumor biology and a distinct mutational profile, both of which carry prognostic significance. Therefore, FDG-PET positivity may be a useful potential risk factor for preoperative risk stratification in primary thyroid carcinoma. This information may help in the planning of subsequent treatment strategy such as the extent of thyroidectomy, prophylactic central neck dissection, and radioiodine ablation. FDG-PET scan has also been found to be a useful adjunct in characterizing indeterminate thyroid nodules on fine needle aspiration cytology. However, larger-sized prospective studies are required to validate this finding. FDG-PET or FDG-PET/CT scan has become the imaging of choice in patients with a negative whole-body radioiodine scan, but with an abnormally raised thyroglobulin level after total thyroidectomy and radioiodine ablation.

Sign in / Sign up

Export Citation Format

Share Document